Taisho To Go Private To Aid 'Dynamic' Restructuring, R&D Investment
$4.8bn MBO Japan's Largest
The largest shareholder in major Japanese pharma firm Taisho, the founding Uehara family, intends to smooth the way to the restructuring and expansion of the business by acquiring and delisting all of its stock. The nearly $5bn size of the deal would makes it the biggest management buyout in Japanese corporate history.
